Skip to Content

Engineering CAR-T/NK for Cancer Immunotherapies

National Cancer Institute-Center for Cancer Research, Bethesda, MD and surrounding area

Position Description:

CAR-T cell-based immunotherapy has shown promising efficacy in some hematologic tumors. However, this approach has shown limitations in major solid tumors including liver cancer and pancreatic cancer. Dr. Mitchell Ho’s laboratory at the National Cancer Institute (NCI) Center for Cancer Research (CCR) has characterized cell surface proteins such as glypicans (GPC3 and GPC2), B7-H3, and mesothelin as tumor-associated targets. To develop next-generation cell-based therapies, we are engineering potent CAR constructs for T or NK cell-based therapies via antibody protein engineering and computational design. Some of our research has led to clinical trials for treating cancer patients. Detailed information about our research program and publications can be accessed:


Candidates are expected to have completed, or be completing, a Ph.D. or M.D./Ph.D. with a strong publication record. Highly motivated candidates who are interested in innovative, high-impact basic and translational research are encouraged to apply. A background in biochemistry, molecular and cell biology, and/or biomedical engineering is required. Evidence with protein structure computational skills is a plus.

To Apply:

Applications should be sent by e-mail to Dr. Mitchell Ho ( Each application should consist of a cover letter describing your research experience and interests, curriculum vitae, bibliography, and contact information of three references.
The NIH is dedicated to building a diverse community in its training and employment programs and encourages the application and nomination of qualified women, minorities, and individuals with disabilitiesDHHS and NIH are Equal Opportunity Employers.